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ABSTRACT
Background: Pregabalin has a similar pharmacologic profile to that of its
evelopmental predecessor gabapentin but has shown greater analgesic activity in
odent models of neuropathic pain.
Objective: The objective of the study was to compare the effects of 2 different
oses of pregabalin and placebo on postoperative pain and morphine consumption.
Methods: Ninety patients who underwent abdominal hysterectomy were in-
luded in the study and randomly divided into 3 groups in a doubled-blinded
anner. They were given 150 mg of pregabalin (group P300, n  30), 300 mg of
regabalin (group P600, n  30), or placebo capsules (group C, n  30) 4 hours
efore the induction of anesthesia; they received a second dose of the drug 12 hours
ostoperatively. Morphine consumption, nausea, and vomiting, visual analogue scale-
ain intensity (VAS-PI), sedation scores, and dissatisfaction scores were recorded in
he postanesthesia care unit (PACU) and at 2, 4, 6, and 24 hours after operation.
Results: Morphine consumption at 24 hours was 40.80 (3.42) mg, 33.79
5.77) mg, and 46.97 (6.67) mg in groups P300, P600, and C, respectively (P 
.001). VAS-PI scores at movement and at rest in the PACU and at 2, 4, and 6 hours
ecreased in group P600 (P  0.01). In the PACU and at 2, 4, and 6 hours, the
sedation scores were increased in group P600 compared with the scores in group C
(P  0.001, P  0.001, P  0.01, P  0.006, respectively). Patient satisfaction was
higher in group P600 than in group C for all time points (P  0.001, P  0.001,
P  0.001, P  0.001, P  0.001, respectively). There were no statistically
significant differences between the groups for side effects such as nausea, vomiting,
and dizziness (P  0.58).
Conclusions: Pregabalin at a total dose of 600 mg, administered before
peration and at 12 hours postoperatively after abdominal hysterectomy, reduced
orphine consumption and pain intensity and increased patient satisfaction. No
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INTRODUCTION
Pain relief after surgical procedures continues to be a major medical challenge.
Alleviation of pain has been given a high priority by medical professionals and health
authorities. Improvement in perioperative analgesia is not only desirable for human-
itarian reasons but also essential for its potential to reduce postoperative morbidity
and mortality.1,2 Unsatisfactory analgesia increases discomfort of the patient and
prolongs hospital stay.3 This means an increase in the incidence of complications and
treatment costs.3 Moreover, it may lead to development of chronic pain as an adverse
effect, one of the most devastating problems related to this issue if acute pain cannot
be treated as required.4
Postoperative pain is not purely nociceptive in nature and may consist of inflam-
atory, neurogenic, and visceral components.5 Sensitization of the dorsal horn
neurons has been demonstrated in acute pain models and may also play a role in the
development of chronic pain after surgery.6 By reducing the hyperexcitability of
dorsal horn neurons induced by tissue damage, gabapentin and pregabalin may have
roles in the treatment of postoperative pain.7,8
Pregabalin is the pharmacologically active S-enantiomer of 3-aminomethyl-5-
ethyl-hexanoic acid.9 It is a structural analogue of -aminobutyric acid, one of
the key inhibitory neurotransmitters in the brain. Its mode of action is believed
to be mediated by the -2--1 subunit protein of voltage-gated calcium chan-
nels, resulting in its anxiolytic, anticonvulsant, and antinociceptive effects.10
Pregabalin is rapidly absorbed with peak blood concentrations occurring within
1 hour. The average bioavailability exceeds 90% and is independent of dose,
which may produce a more predictable patient response. The elimination half-life
of pregabalin ranges between 5.5 and 6.7 hours and is independent of dose.9,11
Due to these specific properties of pregabalin, preoperative single dose adminis-
tration is effective in postoperative pain therapy with no need for long-term
treatment.12
Although opioids continue to have an important role in postoperative pain man-
gement, they have side effects.13,14 For this reason, multimodal analgesia was
suggested to improve postoperative analgesia and to reduce opioid-related side
effects.15 An antineuropathic pain drug like pregabalin, as a part of multimodal
nalgesia, can be useful for optimization of postoperative analgesia.7,8,12,16 Early
preclinical studies suggesting analgesic efficacy after tissue injury led to the devel-
opment of gabapentin and pregabalin as treatments for postoperative pain.17,18
Preoperative administration of 600 mg pregabalin, but not 300 mg, significantly
reduced opioid usage in patients after laparoscopic hysterectomy.7 In addition, a
Open access under the Elsevier OA license.study reported that 75 and 150 mg doses of pregabalin did not reduce postoperative
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dose was useful to reduce morphine consumption after sleeve gastrectomy.12 In
ontrast, 300 mg pregabalin reduced postoperative opioid usage after abdominal
ysterectomy.16
The aim of the present study was to determine the effect of 2 different doses of oral
regabalin (150 or 300 mg) with the same dose repeated after 12 hours on acute
ostoperative pain control and morphine consumption in a randomized and double-
linded manner.
METHODS
One hundred and five patients were assessed for eligibility; 15 patients were excluded,
and the remaining 90 patients were included in this study. Institutional ethics
committee approval of Inonu University Medical School, Malatya, Turkey, and
written informed consent from each patient were obtained before the study. The
patients (n  90, American Society of Anesthesiologists physical status I and II; age
range, 25–65 years) were scheduled for elective total abdominal hysterectomy under
general anesthesia.
Exclusion criteria were known allergy to opioids or pregabalin, history of
cardiovascular, renal or hepatic disease, psychiatric disorders, chronic pain syn-
dromes, drugs or alcohol abuse, and refusal for participation. Patients receiving
regular opioids or drugs (acetaminophen, NSAIDs, sedatives, or anticonvulsants)
within 24 hours before surgery were also excluded. Patients with systolic arterial
blood pressure levels 160 mm Hg or diastolic arterial blood pressure levels 90
mm Hg were also excluded. In this double-blind study, the patients were
randomly allocated by a computer-generated block randomization procedure to
receive pregabalin or placebo 4 hours before the induction of anesthesia and at 12
hours postoperatively. The researchers and participants were blinded to the drugs
and procedures. The hypothesis that preoperative application of pregabalin would
decrease postoperative opioid requirement with lower visual analogue score-pain
intensity (VAS-PI) and dissatisfaction scores was analyzed. Patient controlled
analgesia (PCA) technique and the verbal numerical rating scale (VAS-PI, 0  no
pain, 10  worst pain imaginable) were explained to the patients during the
reoperative anesthesia consultation.
No patients were premedicated. All the patients fasted from midnight before until
he operation. All the patients were then randomly allocated using computerized
andomization to receive 150 mg of pregabalin (group P300, n  30) or 300 mg of
regabalin (group P600, n  30) as the first study dose 4 hours before the induction
f anesthesia, or as part of the control group (group C, n  30). All the capsules,
ncluding placebo, were prepared by the hospital pharmacy as identical capsules to
aintain blinding. The drugs were obtained by individually prepared opaque enve-
opes by an anesthesiologist with no further involvement in the study. To maintain
linding more properly, all data were obtained and recorded by an anesthesiologist
ho did not participate in this study.
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Current Therapeutic ResearchWith standard hemodynamic monitors in place (electrocardiograph, heart rate,
ulse oxymeter oxygen saturation, noninvasive blood pressure), anesthesia was in-
uced using 2% lidocaine (1 mg/kg), fentanly (1 g/kg), and thiopental (3–5 mg/kg)
ntil the eyelash reflex disappeared. Vecuronium bromide (0.1–0.2 mg/kg) was
dministered to facilitate tracheal intubation and maintained using bolus injections
t a dose of 0.01 mg/kg. Anesthesia was maintained using nitrous oxide 60% and
evoflurane 1.5% to 2.5% in oxygen. The patients were ventilated through controlled
echanical ventilation with an initial tidal volume of 6 to 8 mL/kg, and respiratory
requency of 10 breaths/min was adjusted to maintain the end-tidal carbon dioxide
etween 35 and 40 mm Hg. After skin closure at the end of surgery, the residual
euromuscular blockade was antagonized with intravenous neostigmine (50 g/kg)
nd atropine (20 g/kg). The anesthetic agents were then discontinued, and the
atients were extubated. No further analgesic drugs were administered. All the
atients received PCA with intravenous morphine and were followed for 24 hours,
nd pain and sedation scores were evaluated by study nurses who were blinded to the
tudy protocol. After administration of 5 mg morphine over 30 minutes, starting 15
inutes before the estimated time of completion of surgery, the PCA device was set
o deliver 2 mg of morphine with a lockout of 15 minutes and a 4 hour limit of 20
g, and no continuous infusion. If analgesia was felt to be inadequate at any time
uring the study, the lockout time was shortened to 5 minutes. The primary goal
ith respect to the efficacy of 2 different doses of pregabalin was morphine consump-
ion for 24 hours postoperatively. The secondary goal was to determine VAS-PI at rest
nd at movement, sedation, patient satisfaction with pain control, and number of
atients who experienced side effects (such as respiratory depression, nausea and
omiting, headache, and pruritis). Sedation was assessed using the Ramsay sedation
cale. Patient satisfaction with pain control was assessed on a 4-point scale as 1 very
atisfied, 2  satisfied, 3  neutral, and 4  dissatisfied. Patients were evaluated for
pain scores, morphine consumption, and sedation at 1, 2, 4, 6, and 24 hours
postoperatively. PCA was discontinued when the respiratory rate was 12 breaths/
min or oxygen saturation was 95%. If nausea and vomiting occurred, 10 mg of
metoclopramid was administered intravenously.
Statistical Analysis
The primary outcome of this study was cumulative morphine consumption.
ccordingly, in a 1-way ANOVA study, sample sizes of 30, 30, and 30 from the 3
roups achieved nearly 100% power to detect differences among the means versus the
lternative of equal means using an F test with a 0.05 significance level. Power
nalyses were calculated by PASS software.19 Values are expressed as mean (SD) or
numbers (percent) as appropriate. To evaluate normality, the Shapiro-Wilk test was
performed. The comparisons of the 3 groups were made using 1-way ANOVA with
the post hoc Tukey honestly significant different test for homogeneous variances or
Tamhane’s T2 test for nonhomogeneous variances in multiple comparisons. Cat-
egorical data and postoperative side effects were analyzed by Pearson’s 2 test. A
176
A. Yücel et al.P value  0.05 was considered statistically significant. The statistical analyses
were performed by an expert statistician.
RESULTS
A total of 105 patients who fulfilled the inclusion criteria were considered for
inclusion in the study (Figure). Fifteen patients were excluded from the study
during the preoperative visit. Ninety patients were included in the study.
Demographic characteristics, including age, body weight, height, the duration of
anesthesia, the duration of surgical procedures, and ASA status of the patients in the
3 groups, were not different (Table I). Table II presents the comparison of the results
of the cumulative morphine consumption, pain scores (VAS at rest, VAS at move-
ment), the Ramsay sedation scores, and patient satisfaction scores with respect to the
3 groups.
Morphine consumption at all the evaluation time points was significantly lower in
group P300 compared with group C (P  0.003, P  0.01, P  0.002, P  0.001,
P  0.001, respectively). Similarly, at all the evaluation time points, morphine
consumption was significantly lower in group P600 compared with group C (P 
0.001). Morphine consumption values in the postanesthesia care unit (PACU) and at
2, 4, 6, and 24 hours postoperatively in group P600 were significantly lower than
those of group P300 (P  0.003, P  0.023, P  0.002, P  0.001, P  0.001,
respectively).
Pain scores at rest and at movement in the PACU and at 2, 4, and 6 hours
Figure. Flow diagram of patient distribution. Group C  patients given placebo; Group
P300  patients given 150 mg of pregabalin; Group P600  patients given 300
mg of pregabalin; PCA  patient-controlled anesthesia.postoperatively were significantly lower in group P600 than in groups P300 and C
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higher VAS-PI at rest and at movement at 2, 4, and 6 hours postoperatively in group
P300 than in group P600 (P  0.001, P  0.001, P  0.007, respectively). There
were no differences for all the evaluation time points in pain scores of groups P300
and C at rest and at movement (P 0.19, P 0.31, P 0.35, P 0.68, P 0.80,
respectively).
The sedation scores in the PACU and at 2 hours postoperatively in group P300
were significantly lower than those of group P600 (P  0.03, P  0.005), whereas
the comparison of groups P300 and C revealed significantly higher sedation scores at
2 hours postoperatively in group P300 than those in group C (P  0.004). The
sedation scores in the PACU and at 2, 4, and 6 hours postoperatively in group P600
were significantly higher than those in group C (P  0.001, P  0.001, P  0.01,
P  0.006, respectively).
The patient satisfaction scores in the PACU and at 2, 4, and 24 hours postoper-
atively in group P300 were higher than those in group P600 (P 0.005, P 0.001,
P  0.01, P  0.01, respectively). At all the evaluation time points, the patient
satisfaction scores in group P600 were lower than those in group C (P  0.001, P 
0.001, P  0.001, P  0.001, P  0.001, respectively).
There were no significant differences between the groups for postoperative side
effects such as nausea, vomiting, and dizziness (Table III) (P  0.58).
DISCUSSION
The results of this randomized clinical trial showed that perioperative administration
of 2 different doses of oral pregabalin (150 or 300 mg twice, 1 hour before surgery
and 12 hours after the initial dose) was effective in reducing postoperative pain and
provided additional analgesia during the early postoperative period in patients who
underwent total abdominal hysterectomy. There were no significant differences for
Table I. Patient demographic characteristics and duration of anesthesia and surgery. Data
are given as mean (SD) or number of patients.
Variable
P300
(n  30)
P600
(n  30)
Control
(n  30)
Age, y 46.4 (9.1) 43.27 (7.40) 42.47 (9.31)
Weight, kg 68.80 (9.2) 70.90 (10.23) 70.66 (10.03)
Height, cm 159.90 (5.08) 162.40 (8.15) 162.43 (6.66)
Duration of anesthesia, min 108.43 (13.53) 104.83 (16.05) 104.67 (16.50)
Duration of surgical procedures, min 89.33 (18.18) 84.67 (12.92) 86 (17.58)
ASA I/II 23/7 23/7 20/10
ASA  American Society of Anesthesiologists; Control  patients given placebo; P300  patients given
150 mg of pregabalin; P600  patients given 300 mg of pregabalin.side effects (postoperative nausea or vomiting and dizziness) among the 3 groups. The
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as mean (SD).
Variable
P300
(n  30)
P600
(n  30)
Control
(n  30) P ‡
Cumulative morphine
consumption
PACU 8.03 (0.81)*† 6.93 (0.83)† 9.17 (0.38) 0.001
2 h 13.03 (1.30)*† 11.37 (2.17)† 14.77 (1.45) 0.001
4 h 20.63 (3.13)*† 17.20 (3.12)† 23.90 (3.20) 0.001
6 h 27.70 (3.01)*† 22.67 (4.27)† 32.60 (5.30) 0.001
24 h 40.80 (3.42)*† 33.79 (5.77)† 46.97 (6.67) 0.001
AS rest
PACU 7.0 (0.7)* 5.50 (0.51)† 7.20 (0.61) 0.001
2 h 6.03 (0.66)* 4.37 (0.49)† 6.23 (0.56) 0.001
4 h 5.10 (0.75)* 3.57 (0.72)† 5.30 (0.59) 0.001
6 h 3.20 (0.60)* 2.53 (0.7)† 3.33 (1.0) 0.001
24 h 1.57 (0.6) 1.47 (0.5) 1.73 (0.9) 0.39
AS movement
PACU 7.97 (0.5)* 6.9 (0.6)† 8.27 (0.6) 0.001
2 h 6.80 (0.6)* 6.17 (0.6)† 7 (0.8) 0.001
4 h 5.6 (0.7)* 4.97 (0.49)† 5.83 (0.9) 0.001
6 h 4.23 (0.6)* 3.57 (0.6)† 4.40 (1.0) 0.001
24 h 2.57 (0.6) 2.43 (0.9) 2.73 (0.9) 0.40
amsay sedation score
PACU 2.53 (0.51)* 2.87 (0.51)† 2.33 (0.48) 0.001
2 h 2.40 (0.56)*† 2.77 (0.43)† 2.03 (0.32) 0.001
4 h 1.83 (0.53) 1.93 (0.25)† 1.60 (0.50) 0.01
6 h 1.50 (0.63) 1.67 (0.48)† 1.27 (0.45) 0.01
24 h 1.10 (0.31) 1.23 (0.50) 1.10 (0.31) 0.30
atient satisfaction score
PACU 3.17 (0.37)* 2.73 (0.4)† 3.30 (0.5) 0.001
2 h 2.87 (0.34)* 2.20 (0.4)† 2.97 (0.18) 0.001
4 h 2.23 (0.4)* 1.87 (0.3)† 2.40 (0.49) 0.001
6 h 1.63 (0.4) 1.37 (0.4)† 1.9 (0.60) 0.001
24 h 1.23 (0.43)* 0.93 (0.2)† 1.43 (0.50) 0.001
P300  patients given 150 mg of pregabalin; P600  patients given 300 mg of pregabalin; PACU 
postanesthesia care unit; VAS  visual analogue scale.
*Significantly different compared with P600 (P  0.05).
†Significantly different compared with control (P  0.05).
‡1-way ANOVA test.
179
t
b
c
a
g
o
r
c
p
f
m
q
p
m
D
Current Therapeutic Researchpregabalin groups also had significantly lower VAS-PI scores and higher patient
satisfaction in the first postoperative 24 hours than the control group.
Various classes of analgesics have been used in reducing postoperative pain. Recent
studies about postoperative pain care demonstrated that the combinations of various
antihyperalgesics, such as gabapentin and analgesic drugs, might reduce pain, the
need for opioid analgesics, and side effects.11,18 Therefore, multimodal analgesic
echniques using a number of drugs acting on different analgesic mechanisms are
ecoming increasingly popular.5
The current concept of multimodal postoperative analgesia is mainly based on the
ombination of opioids, NSAIDs or paracetamol, low dose ketamine, anticonvulsants,
nd perioperative administration of local anesthetics. The goal of multimodal anal-
esia is not only the improved quality of analgesia but also reduction in opioid and
ther drug-related side effects.
Dahl et al20 reported that postoperative pain might be considered a transient or
eversible type of neuropathic pain. Therefore, gabapentin and pregabalin, which are
ommonly used in chronic neuropathic pain, are effective in controlling postoperative
ain. A randomized, double-blind, placebo-controlled, parallel-group trial was per-
ormed by Hill et al21 to compare pregabalin 50 and 300 mg with placebo and
ibuprofen 400 mg using a dental pain model. They established that the analgesic
effects of pregabalin 300 mg were as effective as that of ibuprofen 400 mg in a dental
approach to reduce acute postoperative pain. Similar to this study, Jokela et al7
studied doses of 150 or 300 mg twice, at 1 hour before surgery and 12 hours after the
initial dose. They observed that 300 mg of pregabalin was more influential than
pregabalin 150 mg in terms of oxycodone consumption. They also indicated that the
analgesic effect of 300 mg of pregabalin was marginal and that patients experienced
significant side effects.
Mathiesen et al22 demonstrated that a single preoperative dose of pregabalin (300
g) resulted in an almost 50% reduction in 24-hour postoperative morphine re-
uirements in patients who underwent hip surgery. The decrease in 24 hour mor-
hine consumption in this study was nearly 35% (600 mg) and 15% (300 mg). The
ain reason for this difference between the results of the study by Mathiesen et al22
and this study was related to spinal anesthesia. The duration of analgesic effects of
spinal anesthesia significantly decreased morphine consumption in the early postop-
erative period, when the maximum analgesic requirement was unavoidable.
Table III. Adverse events. Data are given as number of events.
Adverse Event
P300
(n  30)
P600
(n  30)
Control
(n  30) Total
Nausea and vomiting 2 5 7 14
Pruritus 5 5 6 16
izziness 10 11 8 29
Total 17 21 21 59
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A. Yücel et al.These studies showed that pregabalin had a significant analgesic effect on acute
ostoperative pain. These results showed that 150 and 300 mg of pregabalin were
ffective in pain relief, management of pain at movement and at rest, use of morphine,
nd patient satisfaction scores.
In contrast, Mathiesen et al23 applied 300 mg pregabalin and 8 mg dexamethasone
n combination with 1000 mg paracetamol 1 hour before anesthesia for pain control
n patients who underwent abdominal hysterectomy. They reported that a combina-
ion of paracetamol and pregabalin or paracetamol and pregabalin and dexamethasone
id not lessen morphine consumption and pain score compared with only paraceta-
ol. The authors concluded that the use of pregabalin with a major visceral ingre-
ient was controversial.
In another study, Jokela et al8 evaluated 90 patients who underwent gynecologic
aparoscopic surgery who were randomized to receive either oral pregabalin 75 or 150
g compared with diazepam 5 mg 1 hour before surgery. Pregabalin 150 mg reduced
ain scores at rest and during mobilization for the first 8 postoperative hours, but it
educed neither pain during cough nor the amount of postoperative analgesic. These
ndings were different from our findings, which might point to a rather limited effect
f pregabalin.
The differences of surgical procedures with comparatively low grade of pain in the
ostoperative period might have limited the ability to detect significant effect of
nalgesics on postoperative pain and the need for opioid analgesic medication. In this
tudy, abdominal hysterectomy patients were preferred as an increase of abdominal
ressure during movement, coughing, and respiration might bring to light the effects
f analgesia.
The conflicting results obtained in a study by White et al24 might be due to the
ifference in the surgical procedures applied in their study. Jokela et al5 observed
ignificantly lower analgesic consumption in laparoscopic surgeries as the analgesic
equirement was lower in such surgeries, and the analgesic sparing effects of periop-
rative administration of pregabalin on postoperative pain were determined only with
he perioperative administration of pregabalin 600 mg, but not with 300 mg.
The main aim of multimodal analgesia was in obtaining effective analgesia and
inimizing possible adverse effects. The prevalence of nausea and vomiting in this
tudy with pregabalin use occurred in 4 of 16 patients with 300 mg and 12 of 18
atients with 600 mg and was higher than the rates found in the study by Jokela et
l7, where dexamethasone was administered to prevent nausea and vomiting, and
oxycodone, ibuprofen, or acetaminophen plus codeine combination was used postop-
eratively to decrease opioid requirement. Adverse events were reported by Hill et al21
more often in the pregabalin 300 group. Of the 50 patients who received 300 mg of
pregabalin, 24 (48%) experienced side effects, most commonly dizziness, somnolence,
and vomiting.
Jokela et al7 reported that the degree of drowsiness was similar after perioperative
administration of diazepam 10 mg and pregabalin 300 or 600 mg. They also
indicated that the incidence of dizziness was higher after perioperative administration
of pregabalin 600 mg during the study. They concluded that the high incidence of
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Current Therapeutic Researchside effects in their study might reflect the female gender of the study population, as
women were more susceptible to the multiple side effects of drugs than men.
The limitations of this study were initiation of treatment with low doses of
pregabalin and gradual increase of the dose to the maximum suggested daily dose of
600 mg. A 600 mg dose of pregabalin, given to a patient unaccustomed to this
medication, might cause adverse effects. However, 600 mg of pregabalin did not
increase the adverse effects. Also, the present study had a small sample size and did
not involve a priori power analysis.
CONCLUSIONS
Preoperative administration of 300 mg of pregabalin with a second dose administered
12 hours after surgery resulted in significant reduction in morphine requirement,
VAS scores at rest and at movement and at cough without increasing the rate of
adverse effects in the postoperative 24 hours in patients who underwent abdominal
hysterectomy. Pregabalin also provided significant patient satisfaction scores.
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